Inovio Pharmaceuticals (NASDAQ:INO) is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.
Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines. Together, these systems aim to improve potency and durability of immune responses, distinguishing Inovio’s approach from traditional vaccine modalities. The company also pursues oncology programs that harness its platform to stimulate immune recognition of tumor-associated antigens.
Inovio’s clinical pipeline includes both prophylactic and therapeutic candidates. Its lead program for an investigational DNA vaccine against COVID-19, INO-4800, has undergone multiple Phase 1 and 2 studies, while programs targeting HPV-driven cancers (INO-3112) and chronic infections such as HIV (INO-5100) continue to advance. Preclinical efforts extend to emerging pathogens and combination strategies in oncology, often conducted in collaboration with academic institutions, global health organizations and government agencies.
Headquartered in Plymouth Meeting, Pennsylvania, Inovio maintains operations in North America, Europe and Asia through partnerships and research collaborations. Since 2016, J. Joseph Kim has served as the company’s Chief Executive Officer, guiding Inovio’s evolution from early-stage research to mid-stage clinical development. With a focus on rapid response and platform versatility, Inovio seeks to address unmet medical needs in both infectious disease prevention and cancer immunotherapy.
